Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L, Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, Stathis A, Politz O, Wengner AM, Bertoni F. Sartori G, et al. Among authors: damia g. Br J Haematol. 2024 Jan;204(1):191-205. doi: 10.1111/bjh.19218. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38011941
Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E, Di Martile M, Brignone M, Di Caprio M, Manni I, Chiappa M, Sergio I, Chiacchiarini M, Bazzichetto C, Conciatori F, D'Aguanno S, D'Angelo C, Ragno R, Russillo M, Colotti G, Marchesi F, Bellone ML, Dal Piaz F, Felli MP, Damia G, Del Bufalo D. Valentini E, et al. Among authors: damia g. Cell Death Dis. 2023 Jul 17;14(7):441. doi: 10.1038/s41419-023-05963-1. Cell Death Dis. 2023. PMID: 37460459 Free PMC article.
Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G. Guffanti F, et al. Among authors: damia g. Br J Cancer. 2023 Mar;128(7):1405. doi: 10.1038/s41416-023-02205-1. Br J Cancer. 2023. PMID: 36797359 Free PMC article. No abstract available.
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
La Verde N, Damia G, Garrone O, Santini D, Fabi A, Ciccarese M, Generali DG, Nunzi M, Poletto E, Ferraris E, Cretella E, Scandurra G, Meattini I, Bertolini AS, Cavanna L, Collovà E, Romagnoli E, Rulli E, Legramandi L, Guffanti F, Bramati A, Moretti A, Cassano A, Vici P, Torri V, Farina G; PAINTER investigators. La Verde N, et al. Among authors: damia g. Breast Cancer Res. 2022 Oct 28;24(1):71. doi: 10.1186/s13058-022-01560-w. Breast Cancer Res. 2022. PMID: 36307826 Free PMC article. Clinical Trial.
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F, Merolla F, Damia G, Ricci F, Varricchio S, Ilardi G, Arenare L, Califano D, Napolitano V, Fruscio R, Melillo RM, Palazzo L, Celetti A. Morra F, et al. Among authors: damia g. J Exp Clin Cancer Res. 2022 Aug 13;41(1):245. doi: 10.1186/s13046-022-02459-2. J Exp Clin Cancer Res. 2022. PMID: 35964058 Free PMC article.
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment.
Chiappa M, Petrella S, Damia G, Broggini M, Guffanti F, Ricci F. Chiappa M, et al. Among authors: damia g. Front Oncol. 2022 Jun 2;12:903016. doi: 10.3389/fonc.2022.903016. eCollection 2022. Front Oncol. 2022. PMID: 35719948 Free PMC article. Review.
235 results